Department of Dermatology

Immune checkpoint blockade (ICB) therapy targets checkpoint proteins to restore normal function to the immune system so that it can attack cancer cells. It is used succes [...]

Immune checkpoint inhibitor (ICI) therapies, such as anti-PD1 and anti-CTLA4, have proved to be clinically effective in numerous malignant diseases due to their ability t [...]

Shared decision-making integrates patient values with clinical evidence and is paramount in patient-doctor collaboration. Dermatology is especially appropriate for such c [...]

Cancer treatment has advanced rapidly in the past decade, with checkpoint inhibitors (CPIs) delivering improved outcomes across a variety of malignant indications. Howeve [...]

Pityriasis rubra pilaris (PRP) is a rare inflammatory cutaneous condition characterized by widespread erythematous scaly plaques and palmoplantar keratoderma. PRP skin in [...]

One of the most important tools for diagnosis, analysis, and study of cancer tissues is immunolabeling. Simultaneously analyzing both expression and spatial data of key s [...]

Melanoma is one of the more aggressive skin cancers with a high mortality rate once it metastasizes. New breakthroughs in the treatment of melanoma have come from the int [...]

Shared decision making (SDM) is a standardized method to integrate patient values with the best clinical evidence. SDM is appropriate for any medical decision with multip [...]

Inpatient dermatology has been shown to improve patient outcomes at a reduced cost. Few hospitals have dermatologists available. Teledermatology may allow dermatologists [...]

Methotrexate is a commonly used medication for inflammatory and autoimmune disorders. Dermatologic literature recommends frequent laboratory monitoring due to the potenti [...]